<DOC>
	<DOCNO>NCT01320033</DOCNO>
	<brief_summary>The primary objective study show CD2475/101 40mg tablet take day 16 week superior placebo Change baseline Week 16 ( Last Observation Carry Forward , Intent To Treat ) inflammatory lesion count .</brief_summary>
	<brief_title>Placebo Controlled Efficacy Safety Study CD2475/101 40 mg Tablets v . Placebo Doxycycline 100 mg Capsules Once Daily Treatment Inflammatory Lesions Acne Vulgaris</brief_title>
	<detailed_description>Investigator 's global assessment lesion count perform study visit .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male female subject 12 year age old acne vulgaris facial involvement A score 3 ( Moderate ) 4 ( Severe ) Investigator 's Global Assessment Scale ( inflammatory ) 25 75 inflammatory lesion ( papule pustule ) face ( include nose ) More two acne nodules/cysts face Acne conglobata , acne fulminans , secondary acne ( chloracne , drug induce acne , etc . ) , severe acne require systemic retinoid treatment Underlying disease dermatologic condition require use interfering topical systemic therapy , limited , atopic dermatitis , perioral dermatitis rosacea Beard facial hair might interfere study assessment plan excessive exposure sun ultraviolet light study ( i.e . natural artificial sunlight , include tan booths sun lamp ) Use oral contraceptive solely control acne Liver function test ALT and/or AST 2.5 time upper limit normal Renal function test serum creatinine 150 umol/L ( 17 mg/L ) high Presence oral genital candidiasis history multiple episodes oral genital candidiasis Females intend conceive child within 5 month follow Baseline visit Males intend conceive child partner study period Requiring concomitant use methoxyflurane</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>acne vulgaris</keyword>
	<keyword>inflammatory lesion</keyword>
</DOC>